Trevena, Inc. (NASDAQ:TRVN) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Wednesday.
According to Zacks, “Trevena, Inc. is a biopharmaceutical company. It focuses on discovering and developing therapeutics for G protein coupled receptors. The Company’s product pipeline includes TRV027, TRV130, TRV734 and Delta opioid biased ligand which are in different clinical phases. Trevena, Inc. is based in King of Prussia, Pennsylvania. “
Several other brokerages have also recently commented on TRVN. Wedbush reaffirmed an “outperform” rating and set a $16.00 price target on shares of Trevena in a research report on Thursday, December 1st. Jefferies Group set a $11.00 target price on shares of Trevena and gave the stock a “buy” rating in a report on Wednesday, January 4th. Brean Capital set a $14.00 target price on shares of Trevena and gave the stock a “buy” rating in a report on Tuesday, October 25th. Oppenheimer Holdings, Inc. began coverage on shares of Trevena in a report on Thursday, January 5th. They issued an “outperform” rating and a $13.00 target price on the stock. Finally, Needham & Company LLC reissued a “buy” rating and issued a $11.00 target price on shares of Trevena in a report on Friday, December 16th. Two investment analysts have rated the stock with a sell rating and eleven have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $13.58.
Shares of Trevena (NASDAQ:TRVN) traded up 0.62% during trading on Wednesday, reaching $6.53. The company had a trading volume of 37,422 shares. The stock has a 50 day moving average of $5.85 and a 200 day moving average of $6.29. Trevena has a 52-week low of $3.76 and a 52-week high of $10.00. The stock’s market capitalization is $341.74 million.
Trevena (NASDAQ:TRVN) last issued its quarterly earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.40) by $0.17. Trevena had a negative return on equity of 66.50% and a negative net margin of 841.00%. Equities research analysts forecast that Trevena will post ($1.91) EPS for the current year.
TRADEMARK VIOLATION WARNING: “Trevena, Inc. (TRVN) Rating Lowered to Sell at Zacks Investment Research” was first published by BBNS and is the sole property of of BBNS. If you are accessing this article on another website, it was copied illegally and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this article can be accessed at https://baseballnewssource.com/markets/trevena-inc-trvn-rating-lowered-to-sell-at-zacks-investment-research/344654.html.
In other Trevena news, CEO Maxine Gowen purchased 12,500 shares of the business’s stock in a transaction dated Monday, November 7th. The shares were bought at an average price of $4.10 per share, with a total value of $51,250.00. Following the completion of the acquisition, the chief executive officer now owns 16,500 shares in the company, valued at approximately $67,650. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 3.40% of the company’s stock.
Several large investors have recently added to or reduced their stakes in TRVN. Citadel Advisors LLC boosted its stake in Trevena by 131.3% in the second quarter. Citadel Advisors LLC now owns 1,160,840 shares of the biopharmaceutical company’s stock worth $7,314,000 after buying an additional 659,048 shares during the period. Baker BROS. Advisors LP acquired a new stake in Trevena during the third quarter worth $3,038,000. BlackRock Fund Advisors boosted its stake in Trevena by 23.6% in the second quarter. BlackRock Fund Advisors now owns 1,834,099 shares of the biopharmaceutical company’s stock worth $11,555,000 after buying an additional 350,089 shares during the period. Northpointe Capital LLC boosted its stake in Trevena by 88.9% in the third quarter. Northpointe Capital LLC now owns 716,102 shares of the biopharmaceutical company’s stock worth $4,834,000 after buying an additional 336,916 shares during the period. Finally, State Street Corp boosted its stake in Trevena by 68.1% in the second quarter. State Street Corp now owns 692,685 shares of the biopharmaceutical company’s stock worth $4,365,000 after buying an additional 280,670 shares during the period. 74.06% of the stock is currently owned by institutional investors.
Trevena Company Profile
Trevena Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and intends to commercialize therapeutics that use an approach to target G protein coupled receptors (GPCRs). Using its product platform, the Company has identified and advanced three differentiated product candidates: Oliceridine (TRV130), TRV027 and TRV250.
Receive News & Ratings for Trevena Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena Inc. and related companies with our FREE daily email newsletter.